Lipigon Pharmaceuticals ABFRA:9RP Quick Ratio is 3.01 as of Dec. 2025, which is 1% below its 10-year median of 3.05. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Lipigon Pharmaceuticals AB ranks worse than 55.6% on this metric.
Lipigon Pharmaceuticals AB has a quick ratio of 3.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lipigon Pharmaceuticals AB's Quick Ratio or its related term are showing as below:
FRA:9RP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.21 Med: 3.05 Max: 6.75
Current: 3.01
During the past 8 years, Lipigon Pharmaceuticals AB's highest Quick Ratio was 6.75. The lowest was 0.21. And the median was 3.05.
FRA:9RP's Quick Ratio is ranked worse than 55.6% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:9RP: 3.01
Lipigon Pharmaceuticals AB (FRA:9RP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lipigon Pharmaceuticals AB Quick Ratio Related Terms
Lipigon Pharmaceuticals AB Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9RP vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipigon Pharmaceuticals AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lipigon Pharmaceuticals AB's Quick Ratio falls into.
Lipigon Pharmaceuticals AB Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipigon Pharmaceuticals AB (FRA:9RP) has a Quick Ratio of 3.01 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lipigon Pharmaceuticals AB and its competitors. This is near median its historical median of 3.05. Over the past decade, Lipigon Pharmaceuticals AB's Quick Ratio has ranged from 0.21 to 6.75. According to the industry distribution chart, Lipigon Pharmaceuticals AB ranks #784 out of 1410 companies in the Biotechnology industry, placing it in the top 55.6%.
Is Lipigon Pharmaceuticals AB's Quick Ratio too high?
Lipigon Pharmaceuticals AB's current Quick Ratio of 3.01 is near median its 10-year median of 3.05. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 6.75. The Biotechnology industry median Quick Ratio is 3.60. Lipigon Pharmaceuticals AB's value of 3.01 is 16.4% below this industry median. Based on the distribution chart, Lipigon Pharmaceuticals AB ranks #784 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint.
How does Lipigon Pharmaceuticals AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lipigon Pharmaceuticals AB ranks #784 out of 1410 companies for Quick Ratio. This places Lipigon Pharmaceuticals AB in the lower half of its industry. The industry median Quick Ratio is 3.60. Lipigon Pharmaceuticals AB's value of 3.01 is 16.4% below this benchmark. Historically, Lipigon Pharmaceuticals AB's own Quick Ratio has ranged from 0.21 to 6.75 over the past decade. While the company's 10-year median is 3.05 vs. the industry median of 3.60, Lipigon Pharmaceuticals AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipigon Pharmaceuticals AB's current Quick Ratio of 3.01 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lipigon Pharmaceuticals AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipigon Pharmaceuticals AB's current Quick Ratio is 3.01, which is near median its own 10-year median of 3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipigon Pharmaceuticals AB stock overvalued right now?
Lipigon Pharmaceuticals AB (FRA:9RP) has a current Quick Ratio of 3.01. The current Quick Ratio is 3.01, which is near median its 10-year median of 3.05 and 16.4% below the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lipigon Pharmaceuticals AB (FRA:9RP), the current Quick Ratio is 3.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9RP has been successfully added to your 